The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children
Open accessAbstract
Importance: Multisystem inflammatory syndrome in children (MIS-C) is the most severe pediatric disease associated with severe acute respiratory syndrome coronavirus 2 infection, potentially life-threatening, but the optimal therapeutic strategy remains unknown. Objective: To compare intravenous immunoglobulins (IVIG) plus methylprednisolone vs IVIG alone as initial therapy in MIS-C. Design, Setting, and Participants: Retrospective cohort study drawn from a national surveillance system with propensity score-matched analysis. All cases with suspected MIS-C were reported to the French National Public Health Agency. Confirmed MIS-C cases fulfilling the World Health Organization definition were included. The study started on April 1, 2020, and follow-up ended on January 6, 2021. Exposures: IVIG and methylprednisolone vs IVIG alone. Main Outcomes and Measures: The primary outcome was persistence of fever 2 days after the introduction of initial therapy or recrudescence of fever within 7 days, which defined treatment failure. Secondary outcomes included a second-line therapy, hemodynamic support, acute left ventricular dysfunction after first-line therapy, and length of stay in the pediatric intensive care unit. The primary analysis involved propensity score matching with a minimum caliper of 0.1. Results: Among 181 children with suspected MIS-C, 111 fulfilled the World Health Organization definition (58 females [52%]; median age, 8.6 years [interquartile range, 4.7 to 12.1]). Five children did not receive either treatment. Overall, 3 of 34 children (9%) in the IVIG and methylprednisolone group and 37 of 72 (51%) in the IVIG alone group did not respond to treatment. Treatment with IVIG and methylprednisolone vs IVIG alone was associated with lower risk of treatment failure (absolute risk difference, -0.28 [95% CI, -0.48 to -0.08]; odds ratio [OR], 0.25 [95% CI, 0.09 to 0.70]; P = .008). IVIG and methylprednisolone therapy vs IVIG alone was also significantly associated with lower risk of use of second-line therapy (absolute risk difference, -0.22 [95% CI, -0.40 to -0.04]; OR, 0.19 [95% CI, 0.06 to 0.61]; P = .004), hemodynamic support (absolute risk difference, -0.17 [95% CI, -0.34 to -0.004]; OR, 0.21 [95% CI, 0.06 to 0.76]), acute left ventricular dysfunction occurring after initial therapy (absolute risk difference, -0.18 [95% CI, -0.35 to -0.01]; OR, 0.20 [95% CI, 0.06 to 0.66]), and duration of stay in the pediatric intensive care unit (median, 4 vs 6 days; difference in days, -2.4 [95% CI, -4.0 to -0.7]). Conclusions and Relevance: Among children with MIS-C, treatment with IVIG and methylprednisolone vs IVIG alone was associated with a more favorable fever course. Study interpretation is limited by the observational design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report
Horby, P., Lim, W. S., Emberson, J., Mafham, M., Bell, J., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., et al. (2020) · doi:10.1101/2020.06.22.20137273 · Cited by 11,475
McCrindle, B. W., Rowley, A. H., Newburger, J. W., Burns, J. C., Bolger, A. F., Gewitz, M., Baker, A. L., Jackson, M. A., Takahashi, M., Shah, P. B., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000484 · Cited by 3,723
Multisystem Inflammatory Syndrome in U.S. Children and Adolescents
Feldstein, L. R., Rose, E. B., Horwitz, S. M., Collins, J. P., Newhams, M. M., Son, M. B. F., Newburger, J. W., Kleinman, L. C., Heidemann, S. M., Martin, A. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2021680 · Cited by 2,643
The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne, J. A. C., Murthy, S., Diaz, J. V., Slutsky, A. S., Villar, J., Angus, D. C., Annane, D., Azevedo, L. C. P., Berwanger, O., et al. (2020) · JAMA · doi:10.1001/jama.2020.17023 · Cited by 2,257
Whittaker, E., Bamford, A., Kenny, J., Kaforou, M., Jones, C. E., Shah, P., Ramnarayan, P., Fraisse, A., Miller, O., Davies, P., et al. (2020) · JAMA · doi:10.1001/jama.2020.10369 · Cited by 1,994
Multisystem Inflammatory Syndrome in Children in New York State
Dufort, E. M., Koumans, E. H., Chow, E. J., Rosenthal, E. M., Muse, A., Rowlands, J., Barranco, M. A., Maxted, A. M., Rosenberg, E. S., Easton, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2021756 · Cited by 1,350
Toubiana, J., Poirault, C., Corsia, A., Bajolle, F., Fourgeaud, J., Angoulvant, F., Debray, A., Basmaci, R., Salvador, E., Biscardi, S., et al. (2020) · BMJ · doi:10.1136/bmj.m2094 · Cited by 1,144
Self-citationBelhadjer, Z., Méot, M., Bajolle, F., Khraiche, D., Legendre, A., Abakka, S., Auriau, J., Grimaud, M., Oualha, M., Beghetti, M., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.048360 · Cited by 1,129
Self-citation
Cited by
Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes
Son, M. B. F., Murray, N., Friedman, K., Young, C. C., Newhams, M. M., Feldstein, L. R., Loftis, L. L., Tarquinio, K. M., Singh, A. R., Heidemann, S. M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102605 · Cited by 366
A guide to immunotherapy for COVID-19
van de Veerdonk, F. L., Giamarellos-Bourboulis, E., Pickkers, P., Derde, L., Leavis, H., van Crevel, R., Engel, J. J., Wiersinga, W. J., Vlaar, A. P. J., Shankar-Hari, M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01643-9 · Cited by 320
Metadata
- Authors
- Ouldali, N., Toubiana, J., Antona, D., Javouhey, E., Madhi, F., Lorrot, M., Léger, P.-L., Galeotti, C., Claude, C., Wiedemann, A., Lachaume, N., Ovaert, C., Dumortier, M., Kahn, J.-E., Mandelcwajg, A., Percheron, L., Biot, B., Bordet, J., Girardin, M.-L., Yang, D. D., Grimaud, M., Oualha, M., Allali, S., Bajolle, F., Beyler, C., Meinzer, U., Levy, M., Paulet, A.-M., Levy, C., Cohen, R., Belot, A., Angoulvant, F., French Covid-19 Paediatric Inflammation Consortium, Rames, C., Donzeau, A., Lety, S., Fedorczuk, C., Lajus, M., Bensaid, P., Laoudi, Y., Pons, C., Beaucourt, C., De Pontual, L., Aupiais, C., Lefevre-Utile, A., Richard, M., Goisque, E., Iriart, X., Brissaud, O., Bailhache, M., Segretin, P., Molimard, J., Orcel, M.-C., Benoist, G., Amouyal, E., Guerder, M., Pouyau, R., De Guillebon De Resnes, J.-M., Mezgueldi, E., Cour-Andlauer, F., Horvat, C., Poinsot, P., Frachette, C., Ouziel, A., Gillet, Y., Barrey, C., Brouard, J., Faucon, C., Ginies, H., Ro, V., Elanga, N., Gajdos, V., Basmaci, R., Danekova, N., Mutar, H., Rouget, S., Torterüe, X., Nattes, E., Hau, I., Biscardi, S., El Jurdi, H., Jung, C., Epaud, R., Delestrain, C., Carlier-Gonod, A., Chavy, C., Colomb, B., Litzler-Renault, S., Semama, D., Huet, F., Sarakbi, M., Mortamet, G., Bost-Bru, C., Kevorkian-Verguet, C., Lachaud, M., Vinit, C., Hentgen, V., Leroux, P., Bertrand, V., Parrod, C., Craiu, I., Kone-Paut, I., Durand, P., Tissiere, P., Morin, L., Miatello, J., Morelle, G., Guiddir, T., Borocco, C., Guillot, C., Leteurtre, S., Dubos, F., Jouancastay, M., Recher, M., Martinot, A., Voeusler, V., Languepin, J., Morand, A., Bosdure, E., Bresson, V., Vanel, N., Ughetto, F., Michel, F., Marie, C., Blonde, R., Nguyen, J., Garrec, N., Chalvon-Demersay, A., Masserot-Lureau, C., Colas, A.-S., Ferrua, C., Larakeb, A., Benkaddouss, S., Mathivon, L., Monfort, M., Naji, S., Carbasse, A., Milesi, C., Schweitzer, C., Giroux, N., Boussard, N., Romefort, B., Launay, E., Gras-Le Guen, C., Ali, A., Blot, N., Tran, A., Rancurel, A., Haas, H., Afanetti, M., Bernardor, J., Talmud, D., Jhaouat, I., Monceaux, F., Chosidow, A., Romain, A.-S., Grimprel, E., Rambaud, J., Jean, S., Starck, J., Levy, Y., Guedj, R., Carbajal, R., Parisot, P., Poncelet, G., Wolff, R., Lacarra, B., Maroni, A., Naudin, J., Geslin, G., Maurice, L., Deho, A., Lebourgeois, F., Chomton, M., Dauger, S., Genuini, M., Benzouid, C., Lokmer, J., Bonnefoy, R., Melki, I., Dingulu, G., Gaschignard, J., Ducrocq, C., Pouletty, M., Corseri, O., Faye, A., Rybak, A., Titomanlio, L., Hurtaux, M.-F., Garcelain, G., Bonacorsi, S., Bidet, P., Birgy, A., Renolleau, S., Lesage, F., Moulin, F., Dupic, L., de Saint Blanquat, L., Heilbronner, C., Vedrenne-Cloquet, M., Salvador, E., Bendavid, M., De Marcellus, C., Chareyre, J., Pinhas, Y., Brisse, J., Taylor, M., Debray, Adnot, P., Chalumeau, M., Abadie, V., Frange, P., Cohen, J. F., Curtis, W., Chappuy, H., Belhadjer, Z., Auriau, J., Méot, M., Houyel, L., Bonnet, D., Delacourt, C., Drummond, D., Bader-Meunier, B., Quartier, P., Delion, F., Blanc, P., Caron, E., Maledon, N., Robert, B., Pantalone, L., Kouider, H., Loeile, C., Loron, G., Vittot, C., Blanc, T., Pinquier, D., Buisson, F., Flodrops, H., Karim, J.-B., Sarton, R., Mokraoui, F., Escoda, S., Deschamps, N., Bonnemains, L., Mahi, S.-L., Mertes, C., Terzic, J., Idier, C., Benezech, A., Simon, T., Decramer, S., Karsenty, C., Brehin, C., Chenichene, S., Ursulescu, N.-M., Manteau, C., Delattre, M., & Dalichoux, B.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2021-03-02
- Volume
- 325
- Issue
- 9
- Pages
- 855
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W3126451306
- Cited by
- 354
- References
- 30
- FWCI
- 66.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children. https://app.cochat.ai/papers/10.1001/jama.2021.0694
- The paper
- Ouldali, N., Toubiana, J., Antona, D., Javouhey, E., Madhi, F., Lorrot, M., Léger, P.-L., Galeotti, C., Claude, C., Wiedemann, A., Lachaume, N., Ovaert, C., Dumortier, M., Kahn, J.-E., Mandelcwajg, A., Percheron, L., Biot, B., Bordet, J., Girardin, M.-L., . . . Dalichoux, B. (2021). Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children. JAMA. https://doi.org/10.1001/jama.2021.0694
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.